Imcheck Therapeutics is a biotechnology company developing ICT41, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9Vδ2 T cells to combat infectious diseases.

Imcheck Therapeutics

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. 

As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. 

Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.  

Bpifrance

Kurma Partners

EQT life science

Idinvest Partners

Wellington Partners

Pfizer Venture Investments

Kinled Holding

Boehringer Ingelheim Venture Fund

Agent Capital

Alexandria Venture Investments

Gimv

Pureos Bioventures

Earlybird Venture Capital

Leukemia & Lymphoma Society

Eurazeo

Invus

ImCheck Therapeutics

Today, on International Women's Day, ImCheck Therapeutics proudly stands with women everywhere, celebrating the remarkable resilience of the women who drive innovation and progress within our organization. 
To the women on our team. Your talent, dedication and fearlessness are the driving force behind our success. We applaud your courage and commitment to excellence.
To our women leaders. Thank you for paving the way and inspiring the next generation of talent with grace. Your vision and determination are invaluable assets to our company.
On this special day, let's continue to champion equality and diversity in the workplace and recognize the collective strength that propels us forward.
 
Together, we can create a more inclusive and empowering environment for all!

In celebration of the 9th International Day of Women and Girls in Science, we salute and celebrate an oustanding team of women who have acted and continue to act as agents of change to accelerate innovation, development and change in our organization. 

Your contributions have shaped this company and we commend your courage, talent and fearlessness. 

To our leaders, we salute you for charting the course, for being trailblazers and for showing our junior employees that they too can pursue their dreams.  

From all of us at ImCheck... Thank You ! 

COM:IMCHECKTHERAPEUTICS

Imcheck Therapeutics

Financials Not Available